Literature DB >> 17363091

Cardiovascular effects of Danshen.

Tsung O Cheng1.   

Abstract

Danshen is one of the most versatile Chinese herbal drugs that have been used for hundred of years in the treatment of numerous ailments. Because of its properties of improving microcirculation, causing coronary vasodilatation, suppressing the formation of thromboxane, inhibiting platelet adhesion and aggregation, and protecting against myocardial ischemia, it is widely used either alone or in combination with other herbal ingredients for patients with coronary artery disease and other cardiovascular diseases, in both China and other countries including the United States. This article provides an overview of its history, pharmacology, pharmacokinetics, clinical applications, side effects, interactions with Western drugs, and future prospects in the management of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363091     DOI: 10.1016/j.ijcard.2007.01.004

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  136 in total

Review 1.  Advances in exploring the role of microRNAs in the pathogenesis, diagnosis and therapy of cardiac diseases in China.

Authors:  Z W Pan; Y J Lu; B F Yang
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

2.  Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: A Randomized controlled trial.

Authors:  Fu-yong Chu; Jie Wang; Kui-wu Yao; Zhi-zhong Li
Journal:  Chin J Integr Med       Date:  2010-06-10       Impact factor: 1.978

3.  Effect of Dan Hong injection on PON1, SOD activity and MDA levels in elderly patients with coronary heart disease.

Authors:  Xianming Su; Yajun He; Wei Yang; Ying Wang; Wei Zhang; Ying Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Danshensu protects vascular endothelia in a rat model of hyperhomocysteinemia.

Authors:  Rui-xue Yang; Shan-ying Huang; Fang-fang Yan; Xiao-ting Lu; Yi-fan Xing; Yan Liu; Yun-fang Liu; Yu-xia Zhao
Journal:  Acta Pharmacol Sin       Date:  2010-09-27       Impact factor: 6.150

5.  Cryptotanshinone inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3/ERK and small GTPase pathways.

Authors:  Yan Luo; Wenxing Chen; Hongyu Zhou; Lei Liu; Tao Shen; J Steven Alexander; Shizhong Zheng; Yin Lu; Shile Huang
Journal:  Cancer Prev Res (Phila)       Date:  2011-08-31

Review 6.  Traditional Chinese medicine: herb-drug interactions with aspirin.

Authors:  Jia Wei Lim; Siow Xian Chee; Wen Jun Wong; Qiu Ling He; Tang Ching Lau
Journal:  Singapore Med J       Date:  2018-05       Impact factor: 1.858

7.  A rapid and low-cost approach to evaluate the allergenicity of herbal injection using HPLC analysis.

Authors:  Li Yu; Guoping Peng; Cunyu Li; Baoping Jiang; Haokun Xu; Ning Ding; Yunfeng Zheng; John Q Leng
Journal:  Fitoterapia       Date:  2013-04-13       Impact factor: 2.882

8.  Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1.

Authors:  Hongli Shan; Xuelian Li; Zhenwei Pan; Li Zhang; Benzhi Cai; Yong Zhang; Chaoqian Xu; Wenfeng Chu; Guofen Qiao; Baoxin Li; Yanjie Lu; Baofeng Yang
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 9.  High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation.

Authors:  Shu Zhu; Wei Li; Mary F Ward; Andrew E Sama; Haichao Wang
Journal:  Inflamm Allergy Drug Targets       Date:  2010-03

10.  Pharmacological effects of Salvia miltiorrhiza (Danshen) on cerebral infarction.

Authors:  Tsai-Hui Lin; Ching-Liang Hsieh
Journal:  Chin Med       Date:  2010-06-21       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.